Basic research

Analysis of cardiac features in Lmna N195K mutant mice using single-nucleus RNA sequencing

  • Wang Junxiao ,
  • Wang Yuze ,
  • Zhang Shasha ,
  • Yuan Yu ,
  • Zhang Bing ,
  • Li Ruogu
Expand
  • 1.Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China
    2.Institute of Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China
Li Ruogu, E-mail: 13564565961@163.com.

Received date: 2025-10-13

  Accepted date: 2025-12-19

  Online published: 2026-03-30

Supported by

National Natural Science Foundation of China(82270298)

Abstract

Objective ·To investigate the cardiac cellular composition and molecular alterations in a dilated cardiomyopathy (DCM) mouse model carrying the Lamin A/C p.Asn195Lys (Lmna N195K) mutation, single-nucleus RNA sequencing (snRNA-seq) was employed to elucidate the mutation′s impact on the cardiac multicellular ecosystem. The pathological phenotypes were systematically characterized in terms of cell type proportions, gene expression profiles, and intercellular communication networks. Methods ·A homozygous Lmna N195K mutant mouse model was generated using clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR-Cas9) technology, with wild-type littermates serving as controls. Cardiac function was evaluated by echocardiography and electrocardiography, while histological analyses, including hematoxylin and eosin (HE) staining, Sirius Red staining, wheat germ agglutinin (WGA) staining, and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, were performed to assess tissue pathology. Nuclei were isolated from cardiac tissue for snRNA-seq, and Seurat (v4.4.0) was applied for cell clustering, differential expression analysis, and subpopulation identification. Pseudotime analysis was used to trace cell state transitions, and CellChat (v1.6.1) was employed to infer intercellular communication networks. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and Western blotting (WB) were conducted to assess the expression of fibrosis markers and LMNA proteins, respectively. Results ·Homozygous Lmna N195K mutant mice exhibited chamber dilation, impaired systolic function, severe cardiac fibrosis, and high mortality. Histological analysis revealed disorganized cardiomyocyte alignment, significantly increased fibrotic area, elevated apoptosis, and reduced LMNA protein expression in the mutant group. SnRNA-seq identified nine major cardiac cell types, including cardiomyocytes, endothelial cells, and fibroblasts. In the mutant group, the proportion of metabolically active cardiomyocytes (CM2) was markedly decreased (P=0.005), while contractile cardiomyocytes (CM3) were increased (P=0.004). Nearly all fibroblasts were converted into a profibrotic subpopulation FB4 (P=0.001). Among endothelial cells, the extracellular matrix (ECM)-secreting subpopulation EC3 was significantly expanded (P=0.007), suggesting the occurrence of endothelial-to-mesenchymal transition (EndoMT). Differential expression analysis revealed dysregulation of genes related to fibrosis, energy metabolism, and cardiac injury. Intercellular communication analysis indicated significant activation of receptor-ligand signaling pathways, including periostin(POSTN)-integrin, vascular endothelial growth factor A(VEGFA)-vascular endothelial growth factor receptor 1(VEGFR1), and Laminin Subunit Alpha 2(LAMA2)-Integrin signaling pathways. Conclusion ·The Lmna N195K mutation disrupts the cardiac multicellular ecosystem, characterized by cardiomyocyte subpopulation imbalance (decreased metabolic cells and increased contractile cells), fibroblast conversion to profibrotic phenotypes, and endothelial EndoMT with enhanced ECM secretion. These alterations, reinforced by aberrant intercellular communication networks, collectively drive fibrosis and pathological remodeling, ultimately leading to dilated cardiomyopathy. This study reveals the impact of Lmna N195K mutation on cardiac cell composition and function at the single cell level, offering critical insights into the cellular basis of LMNA related DCM.

Cite this article

Wang Junxiao , Wang Yuze , Zhang Shasha , Yuan Yu , Zhang Bing , Li Ruogu . Analysis of cardiac features in Lmna N195K mutant mice using single-nucleus RNA sequencing[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2026 , 46(3) : 275 -290 . DOI: 10.3969/j.issn.1674-8115.2026.03.002

References

[1] Broers J L, Ramaekers F C, Bonne G, et al. Nuclear lamins: laminopathies and their role in premature ageing[J]. Physiol Rev, 2006, 86(3): 967-1008.
[2] Fatkin D, MacRae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease[J]. N Engl J Med, 1999, 341(23): 1715-1724.
[3] Worman H J, Fong L G, Muchir A, et al. Laminopathies and the long strange trip from basic cell biology to therapy[J]. J Clin Invest, 2009, 119(7): 1825-1836.
[4] van Berlo J H, de Voogt W G, van der Kooi A J, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death [J]. J Mol Med (Berl), 2005, 83(1): 79-83.
[5] Hasselberg N E, Haland T F, Saberniak J, et al. Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation[J]. Eur Heart J, 2018, 39(10): 853-860.
[6] Nishiuchi S, Makiyama T, Aiba T, et al. Gene-based risk stratification for cardiac disorders in LMNA mutation carriers[J]. Circ Cardiovasc Genet, 2017, 10(6): e001603.
[7] Rosario K F, Karra R, Amos K, et al. LMNA cardiomyopathy: important considerations for the heart failure clinician[J]. J Card Fail, 2023, 29(12): 1657-1666.
[8] Bank E M, Ben-Harush K, Feinstein N, et al. Structural and physiological phenotypes of disease-linked lamin mutations in C. elegans[J]. J Struct Biol, 2012, 177(1): 106-112.
[9] Ito M, Katoh M, Sassa T, et al. LMNA Q353R mutation causes dilated cardiomyopathy through impaired vitamin D signaling[J]. Circulation, 2024, 150(12): 971-974.
[10] Lee J, Termglinchan V, Diecke S, et al. Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy[J]. Nature, 2019, 572(7769): 335-340.
[11] Mounkes L C, Kozlov S V, Rottman J N, et al. Expression of an LMNA-N195K variant of A-type lamins results in cardiac conduction defects and death in mice[J]. Hum Mol Genet, 2005, 14(15): 2167-2180.
[12] Markandeya Y S, Tsubouchi T, Hacker T A, et al. Inhibition of late sodium current attenuates ionic arrhythmia mechanism in ventricular myocytes expressing LaminA-N195K mutation[J]. Heart Rhythm, 2016, 13(11): 2228-2236.
[13] Laurini E, Martinelli V, Lanzicher T, et al. Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins[J]. Cardiovasc Res, 2018, 114(6): 846-857.
[14] Neubauer S. The failing heart: an engine out of fuel[J]. N Engl J Med, 2007, 356(11): 1140-1151.
[15] Lazaropoulos M P, Elrod J W. Mitochondria in pathological cardiac remodeling[J]. Curr Opin Physiol, 2022, 25: 100489.
[16] Doenst T, Nguyen T D, Abel E D. Cardiac metabolism in heart failure: implications beyond ATP production[J]. Circ Res, 2013, 113(6): 709-724.
[17] Scuruchi M, Mannino F, Imbesi C, et al. Biglycan involvement in heart fibrosis: modulation of adenosine 2A receptor improves damage in immortalized cardiac fibroblasts[J]. Int J Mol Sci, 2023, 24(2): 1784.
[18] Wei K, Serpooshan V, Hurtado C, et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart[J]. Nature, 2015, 525(7570): 479-485.
[19] Peters M C, di Martino S, Boelens T, et al. Follistatin-like 1 promotes proliferation of matured human hypoxic iPSC-cardiomyocytes and is secreted by cardiac fibroblasts[J]. Mol Ther Methods Clin Dev, 2022, 25: 3-16.
[20] Koenig A L, Shchukina I, Amrute J, et al. Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure[J]. Nat Cardiovasc Res, 2022, 1(3): 263-280.
[21] Qian C, Dong G L, Yang C M, et al. Broadening horizons: molecular mechanisms and disease implications of endothelial-to-mesenchymal transition[J]. Cell Commun Signal, 2025, 23(1): 16.
[22] Kovacic J C, Dimmeler S, Harvey R P, et al. Endothelial to mesenchymal transition in cardiovascular disease: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2019, 73(2): 190-209.
[23] Souders C A, Bowers S L, Baudino T A. Cardiac fibroblast: the renaissance cell[J]. Circ Res, 2009, 105(12): 1164-1176.
[24] Kedzierski R M, Yanagisawa M. Endothelin system: the double-edged sword in health and disease[J]. Annu Rev Pharmacol Toxicol, 2001, 41: 851-876.
[25] Oka T, Xu J, Kaiser R A, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling[J]. Circ Res, 2007, 101(3): 313-321.
[26] Braile M, Marcella S, Cristinziano L, et al. VEGF-A in cardiomyocytes and heart diseases[J]. Int J Mol Sci, 2020, 21(15): 5294.
[27] Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies[J]. Genes Cancer, 2011, 2(12): 1097-1105.
[28] Aumailley M. The laminin family[J]. Cell Adh Migr, 2013, 7(1): 48-55.
[29] Guo C, Willem M, Werner A, et al. Absence of α7 integrin in dystrophin-deficient mice causes a myopathy similar to Duchenne muscular dystrophy[J]. Hum Mol Genet, 2006, 15(6): 989-998.
[30] Israeli-Rosenberg S, Manso A M, Okada H, et al. Integrins and integrin-associated proteins in the cardiac myocyte[J]. Circ Res, 2014, 114(3): 572-586.
Outlines

/